MedTrace names Peter Juul Kristensen CEO as the company enters a pivotal new phase, advancing toward commercialization and U.S. expansion.
As MedTrace advances toward CE marking and commercialization, with patients and trial sites actively enrolling in the MedTrace Phase III clinical trial, the Board and Interim CEO, Nicholas Borys, have been diligently building the executive leadership team that will guide the company into its next stage of growth. As a next step, Peter Juul Kristensen is appointed CEO.
The new CEO, Peter Juul Kristensen, brings a strong track record in developing go-to-market and business strategies and has successfully led companies across multiple industries — most recently as the Chief Development Officer. His extensive investment experience brings deep insight into market dynamics in both the EU and the US.
With MedTrace’s Phase III trial expected to conclude in the coming 12 months and CE marking underway, the company is entering a strategic new chapter — achieving these critical milestones will pave the way for successful commercialization.
The appointment of the new CEO brings solid expertise to the role, built on Peter’s many years of service as an investor and board member at MedTrace. Prior to starting the CEO role, Peter will step down from the Board. In recent months, he has worked closely with the company as a consultant, further deepening his understanding of MedTrace’s mission and operations. He says:
“I am honored to take on this new role at MedTrace. Having been part of the company’s journey for many years, I am deeply committed to advancing our mission of bringing 15O-water to clinical practice and improving diagnostic accuracy for patients worldwide. I look forward to working with our talented team to drive innovation and growth, particularly as we expand our footprint in the U.S.”
Peter Juul Kristensen’s strong ties to the United States, where he spends a significant amount of time, will be instrumental in supporting MedTrace’s global growth and strategic initiatives.
Nicholas Borys, MD, MedTrace’s Chief Medical Officer (CMO) and Interim CEO, will take on the additional role as President of MedTrace’s U.S. subsidiary while continuing as the CMO. This dual role highlights his expertise and dedication to MedTrace’s mission as the company advances its clinical and commercial goals. His priority as President will be to prepare the U.S. market for commercialization of MedTrace’s 15O-Water system by overseeing the completion of the Phase III clinical trial, submission of the regulatory filings and preparing for the launch in the U.S. market .
Nicholas Borys, President of MedTrace’s U.S. subsidiary and CMO, says:
“MedTrace is at an exciting juncture, and I am thrilled to continue supporting our efforts in the U.S. market while maintaining my role as CMO. Our Phase III trial is a critical step toward making 15O-water a standard diagnostic tool for coronary artery disease, and I am confident in the company’s ability to achieve its ambitious goals now under Peter’s leadership.”
Erik Strömqvist, Chairman of the Board, says:
“We are very pleased that Peter has accepted the position of CEO. Following a thorough recruitment process with strong candidates from both Denmark and the United States, we are confident that Peter – with his experience and deep knowledge of the company, as well as his broad executive experience– has the required foundation and skills to lead MedTrace into its next phase.”
Peter Juul Kristensen will assume the role of CEO, effective November 1, 2025, succeeding the Interim CEO Nicholas Borys, M.D., who has led the company since Ann Kristin Led’s departure in June 2025.
About MedTrace
Founded with a vision to revolutionize diagnostic imaging, MedTrace specializes in radiopharmaceuticals with an ultra-short half-life and is at the forefront of making 15O-water available for clinical practice. The company’s ongoing Phase III clinical trial in the United States is evaluating the diagnostic accuracy and safety of 15O-water as a tracer for PET scans in patients with suspected coronary artery disease.
MedTrace’s innovative technology is already in use in Denmark under magistral exemption and exemption from CE marking issued by the Danish Medicines Agency. The clinical practice at Rigshospitalet in Copenhagen and Aarhus University Hospital in Aarhus has demonstrated the technology’s potential, with the Aarhus University Hospital having scanned over 3,000 patients using 15O-water produced by MedTrace’s system.
For more information, please contact:
Sandra Meersohn Meinecke
[email protected]
+45 53 56 51 61
